CPI-613 (devimistat) + Bendamustine + Rituximab
Relapsed or Refractory Mantle Cell Lymphoma
Key Facts
Indication
Relapsed or Refractory Mantle Cell Lymphoma
Phase
Phase 1
Status
Completed
Company
About Rafael Holdings
Rafael Holdings is a clinical-stage oncology company leveraging its expertise in cancer metabolism to develop innovative therapeutics. Its core asset, CPI-613, is a lipoate analog that disrupts key mitochondrial enzymes, inducing selective cancer cell death. The company is advancing CPI-613 through multiple clinical trials, primarily in combination regimens, and maintains a strategic focus on aggressive and rare cancers with high unmet need.
View full company profile